

Serial No. 09/373,352

IN THE CLAIMS:

Please cancel claims 21 through 36 without prejudice or disclaimer. Applicants note that claims 19 and 20, which are currently pending in the present application, are shown below for clarity.

19. A dosage form comprising:
a core comprising a drug formulation;
an interior membrane formed around the core, the interior membrane comprising 35 wt% to 70 wt% of a polymer possessing a lipophilic-attracting property, 25 wt% to 65 wt% of a flux enhancer, and 0 wt% to 10 wt% of a surfactant; and
an exterior membrane formed around the interior membrane, the exterior membrane comprising 35 wt% to 70 wt% of a polymer permeable to the passage of an aqueous fluid, 10 wt% to 40 wt% of a plasticizer, 20 wt% to 35 wt% of a peptide, and 0 wt% to 10 wt% of a surfactant.
20. The dosage form of claim 19, wherein the interior membrane contacts the exterior membrane, and an exit is present in the interior and exterior membranes for delivering the drug from the dosage form.